Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Cellphire Inc. maintains 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners, which suggests a diversified approach to prosecution even with a small number of active files. The involvement of 2 distinct art units further indicates that the company's research interests in this sector span multiple specialized classifications within the patent office.
The busiest examiner, MATALKAH, FATIMAH KHALAF, is currently handling 1 pending office action. This workload is shared with another examiner who manages the remaining action. For patent practitioners, this distribution means that prosecution strategies must be tailored to two different examiner styles simultaneously. The balance between the 2 distinct examiners and the total pending workload prevents any single examiner from dominating the portfolio's current trajectory.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MATALKAH, FATIMAH KHALAF | 1 | 55.8% | +27.4% |
| KASAYAN, KATRIEL BARCELLANO | 1 | 25.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | KASAYAN, KATRIEL BARCELLANO | 54d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | MATALKAH, FATIMAH KHALAF | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18653905 | METHODS FOR CONTROLLING BLEEDING IN A SUBJECT AFFLICTED WITH HERMANSKY PUDLAK SYNDROME USING PLATELET DERIVATIVE COMPOSITIONS | MATALKAH, FATIMAH KHALAF | 1638 | §103 | Non-Final OA | — | Pending | May 02, 2024 |
| 18341700 | MATERIALS AND METHODS FOR PRODUCING BLOOD PRODUCTS | KASAYAN, KATRIEL BARCELLANO | 1634 | §103§112Other | Non-Final OA | 54d | Pending | Jun 26, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCellphire Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Fatimah Khalaf Matalkah has the most, with 1 of Cellphire Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
